Emerald Advisers LLC Has $356,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Emerald Advisers LLC increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,976 shares of the medical equipment provider’s stock after buying an additional 169 shares during the period. Emerald Advisers LLC’s holdings in Lantheus were worth $356,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in Lantheus during the 3rd quarter worth $25,955,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after buying an additional 3,772 shares during the period. Empirical Asset Management LLC bought a new stake in shares of Lantheus in the 4th quarter valued at about $323,000. Finally, Focus Financial Network Inc. acquired a new stake in shares of Lantheus in the fourth quarter valued at about $292,000. 99.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday. JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. Finally, Truist Financial lifted their price objective on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average target price of $129.43.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by corporate insiders.

Lantheus Price Performance

LNTH stock opened at $97.71 on Monday. The company’s 50-day moving average is $92.67 and its 200-day moving average is $96.51. The stock has a market capitalization of $6.69 billion, a PE ratio of 16.26 and a beta of 0.38. Lantheus Holdings, Inc. has a 1 year low of $57.92 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. On average, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.